

1 The Honorable Robert J. Bryan  
2  
3  
4  
5  
6  
7  
8  
9

10 UNITED STATES DISTRICT COURT FOR THE  
11 WESTERN DISTRICT OF WASHINGTON  
12 AT TACOMA  
13  
14

15 UNITED STATES OF AMERICA,  
16 Plaintiff,  
17  
18 v.  
19 RICHARD MARSCHALL,  
20 Defendant.  
21

NO. CR20-5270 RJB

**GOVERNMENT'S TRIAL BRIEF**

22 The United States of America, by and through Tessa M. Gorman, Acting United  
23 States Attorney for the Western District of Washington, and Marie M. Dalton and  
24 Nicholas Manheim, Assistant United States Attorneys, respectfully submits this Trial  
25 Brief. Trial is scheduled to begin on August 2, 2021.

26 **I. SUMMARY OF THE CASE**

27 **A. The Defendant's Background**

28 Defendant Richard Marschall is a former naturopathic physician (N.D.) who was  
29 twice convicted in United States District Court of Introduction of a Misbranded Drug into  
30 Interstate Commerce, in violation of 21 U.S.C. §§ 331(a) and 333(a)(2). In 2011, the  
31 Defendant admitted that he distributed Human Chorionic Gonadotropin (HCG), a drug  
32

1 approved to treat infertility, distributing it as a weight loss drug.<sup>1</sup> In committing that  
 2 offense, the Defendant imported HCG from India, providing this drug to patients whom  
 3 the Defendant had only consulted with over the telephone. When questioned regarding  
 4 the importation of HCG, the Defendant lied to an FDA official, claiming he was an  
 5 endocrinologist and used HCG to treat infertile patients. After this conviction, the  
 6 Defendant's naturopathy license was suspended by the Washington Department of  
 7 Health.

8 In 2017, the Defendant was again convicted of Introduction of Misbranded Drugs  
 9 into Interstate Commerce, in violation of 21 U.S.C. §§ 331(a) and 333(a)(2). Despite his  
 10 prior conviction, the Defendant again sold HCG to approximately sixty patients to  
 11 promote weight loss.<sup>2</sup> After the second conviction, in 2018, the Washington Department  
 12 of Health permanently revoked his credential as a naturopathic physician. Additionally,  
 13 an Agreed Order and Judgment was entered in the Thurston County Superior Court,  
 14 permanently enjoining the Defendant from practicing naturopathic medicine and  
 15 representing himself to be a naturopath—including by using the titles “‘Doctor’, ‘ND’,  
 16 ‘naturopath’, or any similar title.”<sup>3</sup>

17 **B. The Defendant Distributes the Dynamic Duo to Treat, Prevent, and Cure  
 18 COVID-19 and Other Ailments**

19 Beginning in March 2020, as COVID-19 was spreading globally and throughout  
 20 Washington State, the Defendant again introduced misbranded drugs into interstate  
 21 commerce. Despite having his naturopathy credential revoked, the Defendant posted on  
 22 Facebook that he had developed a product, known as the “Dynamic Duo,” that could treat  
 23 or cure COVID-19, along with other viruses and medical conditions. Specifically, on  
 24 Facebook, the Defendant claimed that the products Allimed (garlic extract) and IAG

25  
 26  
 27 <sup>1</sup> See *United States v. Marschall*, CR 11-5222 BHS, (W.D. Wa. 2011) ECF No. 7, Plea Agreement at 4-6.  
 28 <sup>2</sup> See *United States v. Marschall*, CR 17-5226 RBL, (W.D. Wa. 2017) ECF No. 8, Plea Agreement at 4-5.  
<sup>3</sup> *Washington State Department of Health v. Richard A. Marschall*, No. 18-2-00809-34, (Wa. Sup. Ct. 2018), Agreed  
 Upon Order and Judgment.

1 Arabinogalactans (larch tree starch) could “***prevent or treat*** viral, bacterial, fungal, and  
 2 parasitic infections.” (emphasis added). The Defendant also claimed that these two  
 3 products:

4 [C]an boost the immune system so it can fight for you but ***even more***  
 5 ***importantly*** while your immune system is being strengthened, ***can crush***,  
 6 30 different viral infections including those in the Corona family like in  
 7 China, 40 different bacterial infections, 25 different fungal infections and  
 20 different parasitic infections like amoeba.

8 (emphasis added).

9 In addition, the Defendant’s wife, Rose Marschall, also posted claims on her  
 10 Facebook, instructing individuals to call her husband to purchase the Dynamic Duo  
 11 products. Based on her Facebook posts, along with other information learned during the  
 12 course of this investigation, Rose Marschall appears to promote her husband’s practice,  
 13 advertising his treatments, and drumming up business for his practice. For example, on  
 14 March 21, 2020, Rose Marschall posted the following on Facebook: “The Dynamic Duo  
 15 knocked out my very bad cough/cold in February. ***Corona?*** Want info? Call [the  
 16 Defendant’s telephone number].” (emphasis added). Additionally, Rose Marschall  
 17 responded to others’ posts, again advertising her husband’s products. For example, on  
 18 March 24, 2020, T.W. claimed on Facebook that the United States could be the next  
 19 epicenter of the COVID-19 pandemic and noted that there was no vaccine or medication  
 20 to fight the virus. In response, Rose Marschall replied “***there are two products that may***  
 21 ***be able to stop this.*** Call and talk to Rick about what we are calling the Dynamic Duo:  
 22 [listing the Defendant’s telephone number].” (emphasis added).

23 In response to these posts, a number of concerned citizens, including Karen Hogan  
 24 and Steve Koehler, contacted the U.S. Attorney’s Office, complaining that the Defendant  
 25 was peddling an unproven COVID-19 treatment despite having his naturopathy license  
 26 revoked. After receiving these complaints, and reviewing these Facebook posts, on  
 27 March 30, 2020, an undercover FDA agent contacted the Defendant, recording their  
 28 telephone call. On this call, the Defendant again advised the undercover agent that the

1 Dynamic Duo products could prevent, cure, or treat COVID-19. Specifically, the  
 2 Defendant told the agent: “Allicin doesn’t boost the immune system, *it just kills the*  
 3 *virus.*” (emphasis added). The Defendant explained:

4 You buy it and you leave and you walk away ... You know if you have  
 5 evidence that you’re getting sick how does it show up? .... You know its  
 6 its ah the cough keeps coming on right? *Or your temperature goes up, in*  
*this case with the Covid.* With the regular flu your temperature might not  
 7 go up very fast. *With this one it seems to go up faster.* And the cough,  
 8 and *then this this new virus this you know it’s hitting people.* It’s going  
 9 right to their right to their lungs and you know deep in their lungs. It’s not  
 like you know just bronchitis its pneumonia. You know it’s killing people  
 quickly.

10  
 11 Immediately after describing the deadly nature of COVID-19, the Defendant then stated  
 12 *“here’s what I can do,”* proceeding to sell the undercover agent the Dynamic Duo  
 13 products. In doing so, the Defendant claimed that “unfortunately, because everybody  
 14 wants the stuff, you know, there’s—there’s a bit of a wait.”

15 The following day, the Defendant called the undercover agent back, advising her  
 16 that he was able to obtain the Dynamic Duo products. In response, the agent purchased  
 17 these products for \$140 plus shipping. The Defendant shipped the products in interstate  
 18 commerce, from Port Angeles, Washington, to the undercover agent in Oakland,  
 19 California. In addition to the bottles, the package also contained several written  
 20 statements by the Defendant, including a document titled “BE PREPARED,” which again  
 21 claimed that the products “can crush 30 different viral infections, *including those in the*  
*Corona family, (like in China Corona-19),* 40 different bacterial infections, 25 different  
 22 fungal infections and 20 different parasitic infections like amoebas.” The package also  
 23 contained a document titled “The Dynamic Duo Instructions,” noting that the products  
 24 were “For **Treatment** Only,” and advising the user to take them “at the VERY FIRST  
 25 SIGN of flu or cold like symptoms,” including “a cough, a sneeze, a sore throat, a runny  
 26 nose that is NOT allergy related.” (emphasis added). Additionally, on several of the  
 27 documents accompanying the pills, the Defendant listed his name as “Rick Marschall,  
 28

1 N.D.” For example, he listed this name and title on the documents entitled “The  
 2 Dynamic Duo Instructions,” and “Preparing for Viral Infections with Plant Medicines  
 3 Since Antibiotics Can’t Help: Introducing the ‘Dynamic Duo.’” Additionally, the  
 4 Defendant listed his name as “Rick Marschall ND” on an email sent to the undercover  
 5 agent on March 31, 2020.

6 Based on this conduct, on April 29, 2020, a Complaint was filed, charging the  
 7 Defendant with Introduction of Misbranded Drugs into Interstate Commerce, in violation  
 8 of 21 U.S.C. §§ 331(a) and 333(a)(2). Dkt. 1. On August 5, 2020, an Indictment was  
 9 filed, charging the Defendant with the same offense, alleging that the Dynamic Duo  
 10 products were drugs that were misbranded in four ways:

- 11 (1) The labeling accompanying the Dynamic Duo products was false and  
 12 misleading in some particular, in that it suggested that RICHARD  
 13 MARSCHALL was a naturopathic doctor by listing him as “Rick Marschall  
 14 N.D.”;
- 15 (2) The Dynamic Duo products were prescription drugs and the drugs were  
 16 dispensed without a prescription;
- 17 (3) The labeling accompanying the Dynamic Duo products failed to bear  
 18 adequate directions for use because the Dynamic Duo products were  
 19 prescription drugs because the Dynamic Duo products’ method of use, and  
 20 the collateral means necessary for their use, rendered them not safe for use  
 21 except under the supervision of a licensed practitioner; and
- 22 (4) The Dynamic Duo products were manufactured, prepared, propagated,  
 23 compounded and processed in establishments not registered with the Food  
 24 and Drug Administration, and the Dynamic Duo products were not included  
 25 in any list of drugs manufactured, prepared, propagated, compounded, and  
 26 processed in a registered establishment.

27 Dkt. 38.

## II. ELEMENTS OF THE OFFENSE

## A. Introduction of Misbranded Drugs into Interstate Commerce

In Count One, the Defendant is charged with Introduction of Misbranded Drugs into Interstate Commerce, in violation of Title 21, United States Code Sections 331(a) and 333(a)(2). The elements of that offense are as follows:

- (1) The Defendant introduced or caused the introduction of the Dynamic Duo products into interstate commerce;
- (2) The Dynamic Duo products were drugs;
- (3) The Dynamic Duo products were misbranded; and
- (4) The Defendant committed the offense after a previous conviction of him under Title 21, Section 333(a)(2) had become final.

In proving that the Dynamic Duo products were misbranded, the government will show:

- (1) the Dynamic Duo products' labeling was false and misleading in some particular, in that it suggested that the Defendant was a naturopathic doctor by listing him as "Rick Marschall N.D.";
- (2) The Dynamic Duo products were prescription drugs, and the drugs were dispensed without a prescription;
- (3) The Dynamic Duo products' labeling failed to bear adequate directions for use because the drugs were prescription drugs because the drugs' method of use, and the collateral means necessary for their use, rendered them not safe for use except under the supervision of a licensed practitioner; or
- (4) The Dynamic Duo products were not included in any list of drugs manufactured, prepared, propagated, compounded, and processed in a registered establishment.<sup>4</sup>

<sup>4</sup> Although the Indictment charged two unique registration violations, for simplicity, at trial the government intends only to prove one of the registration violations: that the products “were not included in any list of drugs manufactured, prepared, propagated, compounded, and processed in a registered establishment.”

1

### 2 III. LEGAL ISSUES

3 **A. Elements of Charged Offense**

4 The Defendant is charged with one count of Introduction of Misbranded Drugs  
 5 into Interstate Commerce in violation of 21 U.S.C. § 331(a) and 333(a)(2). Section  
 6 331(a) prohibits “the introduction or delivery for introduction into interstate commerce of  
 7 any . . . drug . . . that is . . . misbranded.” Section 333 establishes two tiers of penalties  
 8 for such misbranding, a misdemeanor offense in § 333(a)(1) and a felony offense in  
 9 § 333(a)(2). For a person to be convicted of the felony offense, he must commit the acts  
 10 prohibited under § 333(a) and also meet one of two other requirements. Either the person  
 11 must violate § 333(a) with “the intent to defraud or mislead,” or the person must violate  
 12 § 333(a) “after a conviction of him under this section has become final.” Here, the  
 13 Defendant is charged under the second of these requirements because he has twice been  
 14 convicted of committing the same crime, first in 2011 and again in 2017. The  
 15 government has submitted its proposed jury instructions listing this second requirement—  
 16 that the Defendant committed the current offense after a conviction of him under the  
 17 statute had become final—as an element that should be decided by the jury.

18 While the government is not aware of binding precedent holding that this specific  
 19 provision of 21 U.S.C. § 333(a) is an element, there is binding precedent that the alternate  
 20 requirement to prove the defendant’s “intent to defraud or mislead” is an element. *See*  
 21 *United States v. Watkins*, 278 F.3d 961, 964 (9th Cir. 2002) (intent to defraud or mislead  
 22 is “an additional mens rea element that is absent from the broader-reaching misdemeanor  
 23 provision”); *United States v. Geborde*, 278 F.3d 926, 929 (9th Cir. 2002) (the jury “found  
 24 the intent to defraud or mislead”); *United States v. Smith*, 714 F. App’x 701, 704 (9th Cir.  
 25 2017) (district court did not err in instructing the jury to consider whether defendant  
 26 “acted with the intent to defraud or mislead when he introduced MMS products into  
 27 interstate commerce”—an “accurate statement of the law and consistent with the charged  
 28 statutes”); *United States v. Xin He*, 405 F. App’x 220, 221 (9th Cir. 2010) (in an appeal

TRIAL BRIEF

*United States v. Marschall* - 7

UNITED STATES ATTORNEY  
 700 STEWART STREET, SUITE 5220  
 SEATTLE, WASHINGTON 98101  
 (206) 553-7970

1 from a trial, rejecting defendant's sufficiency challenge, treating § 333(a)(2)'s *mens rea*  
 2 prong as an element, and finding the trial evidence sufficient to "lead a rational fact  
 3 finder to conclude beyond a reasonable doubt that [defendant] had the requisite intent to  
 4 defraud or mislead in connection with offering a misbranded drug for sale"). Section  
 5 333(a)(2) separates the "intent to defraud or mislead" element from the previous  
 6 conviction requirement with only a comma and "or," thus indicating that the "intent to  
 7 defraud or mislead" element and the previous conviction requirement share the same  
 8 purpose in the statutory scheme and are alternative ways to prove the crime occurred.  
 9 Consequently, because the "intent to defraud or mislead" requirement is an element to be  
 10 decided by the jury, it appears the previous conviction requirement is as well. Out of an  
 11 abundance of caution, and to ensure that the jury make all necessary findings, the  
 12 government's proposed jury instructions include the previous conviction requirement as  
 13 an element that the jury must find to convict.

14 **B. Expert Witnesses**

15 The government expects to introduce testimony from an expert witness, whose  
 16 identity and testimony have been disclosed to defense counsel. Specifically, Dr. Arthur  
 17 Simone will provide testimony, including:

- 18 (1) Medical expertise is required to diagnose COVID-19, viral infections, parasitic  
     infections, methicillin-resistant *Staphylococcus aureus* (MRSA).
- 19 (2) Medical expertise is needed to determine the most appropriate course of  
     therapy for patients with these conditions.
- 20 (3) The use of a product to treat COVID-19, not under the supervision of a  
     licensed practitioner, poses risks to the individual user, for example, use of the  
     product by patients with the disease can permit the disease to progress while  
     delaying potentially lifesaving treatment.
- 21 (4) The use of a product to treat COVID-19, not under the supervision of a  
     licensed practitioner, poses risks to the public, for example, use of the product  
     by patients during a pandemic gives users a false impression that they need not

1 rigorously adhere to interventions such as social distancing, use of protective  
 2 equipment, self-quarantining after exposure, and other good hygienic practices.

3 The Court has already ruled on a motion *in limine* regarding Dr. Simone's testimony and  
 4 has deemed these opinions admissible. Dkt. 114.

5 This testimony is admissible pursuant to Federal Rule of Evidence 702, which  
 6 provides that “[i]f scientific, technical, or other specialized knowledge will assist the trier  
 7 of fact to understand the evidence or to determine a fact in issue, a witness qualified as an  
 8 expert by knowledge, skill, experience, training, or education, may testify thereto.” The  
 9 decision to admit expert testimony “is committed to the discretion of the [trial] court and  
 10 will not be disturbed [on appeal] unless manifestly erroneous.” *United States v. Kinsey*,  
 11 843 F.2d 383, 388 (9th Cir. 1988).

12 To the extent that an expert's testimony is based upon information obtained other  
 13 than through personal observation, it is permissible if it is based upon information of the  
 14 type reasonably relied upon by experts in forming expert opinions. *See United States v.*  
 15 *Wright*, 215 F.3d 1020 (9th Cir. 2000) (holding that expert testimony regarding DNA  
 16 testimony satisfied the Supreme Court's *Daubert* standard for the admissibility of  
 17 scientific evidence); *United States v. Golden*, 532 F.2d 1244 (9th Cir. 1976) (holding it  
 18 proper to admit DEA agent's testimony about market value of methamphetamine where  
 19 that testimony was based in part upon information obtained from other undercover  
 20 agents, because such information is of the type reasonably relied upon by experts  
 21 determining prevailing prices in clandestine markets).

22 In contrast, the defense has indicated that it may call an expert witness to testify  
 23 that “the two supplements, referred to as the Dynamic Duo, help to boost the immune  
 24 system and that a strong immune system helps decrease negative outcomes associated  
 25 with viruses.” The government has filed a motion *in limine* to exclude this testimony as  
 26 improperly disclosed under Rule 16(b)(1)(C), and irrelevant and inadmissible under  
 27 Rules 402 and 403, and under *Daubert v. Merrell Dow Pharmaceuticals*, 509 U.S. 579,  
 28 590 (1993).

1   **C. Statements of the Defendant**

2       The government intends to offer into evidence excerpts of the Defendant's  
 3 Facebook posts, written materials, and recorded telephone conversations. Such  
 4 statements by a defendant are not hearsay when offered by the government against the  
 5 speaker. Fed. R. Evid. 801(d)(2). However, the converse is not true; a defendant is not  
 6 entitled to admit any of his own out-of-court statements. An out-of-court statement of a  
 7 declarant offered by the declarant on his own behalf is inadmissible hearsay because,  
 8 among other things, it is not a statement by a party-opponent. *See United States v.*  
 9 *Ortega*, 203 F.3d 675, 682 (9th Cir. 2000); *see also Williamson v. United States*, 512 U.S.  
 10 594, 600 (1994) (the hearsay rule excludes self-serving statements because such  
 11 statements "are exactly the ones which people are most likely to make even when they  
 12 are false").

13       The government may offer a transcript of the audio recording it introduces into  
 14 evidence to the jury as a listening aid. The government will shortly be providing the  
 15 transcripts to defense counsel. The Ninth Circuit has held that it is not an abuse of  
 16 discretion for a court to allow jurors to view transcripts of recordings as listening aids  
 17 where a participant in the conversation testifies that the transcripts are accurate, jurors are  
 18 not permitted to look at the transcripts until the recordings are played, the transcripts are  
 19 not admitted into evidence, and the district court instructs jurors that only the recordings  
 20 are evidence and that, in the event of a discrepancy between the recording and the  
 21 transcript the recording controls. *United States v. Booker*, 952 F.2d 247, 249 (9th Cir.  
 22 1991).

23       In this case, the government has provided copies of the transcript that it intends to  
 24 use to the witnesses through whom the government intends to play recordings, and those  
 25 persons will testify that the transcript is accurate. Before transcripts are distributed to the  
 26 jury, the Court should read Model Ninth Circuit Jury Instruction 2.7, and, before  
 27 subsequent recordings are played, the Court should remind the jury that only the  
 28 recordings are evidence and that, if there are any discrepancies between recordings and

TRIAL BRIEF

*United States v. Marschall* - 10

UNITED STATES ATTORNEY  
 700 STEWART STREET, SUITE 5220  
 SEATTLE, WASHINGTON 98101  
 (206) 553-7970

1 transcripts, recordings control. *Id.* In addition, if defense counsel disputes the accuracy  
 2 of the transcripts, the Court should review any disputed portions for accuracy. *See id.* at  
 3 248; *see also United States v. Turner*, 528 F.2d 143 (9th Cir. 1975) (permitting jurors to  
 4 use transcripts again when jurors requested that tape recordings be replayed during their  
 5 deliberation).

6 **D. Other Out-of-Court Statements Offered for Non-Hearsay Purposes**

7 “Hearsay is a statement, other than one made by the declarant while testifying at  
 8 the trial or hearing, offered in evidence to prove the truth of the matter asserted.” Fed. R.  
 9 Evid. 801(c). The admission of hearsay into evidence is generally proscribed by Rule  
 10 802. When it is relevant that an out of court statement was made, however, and the  
 11 statement is offered exclusively to prove that it was made, it is not hearsay and is  
 12 therefore admissible. *See Williams v. United States*, 458 U.S. 279 (1982). That is  
 13 because statements not offered for their truth are not hearsay. Fed. R. Evid. 801(c).

14 In certain instances, the government may offer out-of-court statements not to  
 15 prove the truth of the matters asserted, but merely to explain information possessed by,  
 16 and the subsequent actions of, the investigative agents, law enforcement officers, and  
 17 other witnesses. For example, this case was initiated after witnesses conveyed  
 18 information to law enforcement officers regarding statements made by the Defendant and  
 19 his wife. Because these statements will not be offered for the truth of the matter asserted,  
 20 the statements would not constitute hearsay as defined by Rule 801(c). *See United States*  
 21 *v. Mitchell*, 502 F.3d 931, 969 (9th Cir. 2007) (no error in allowing investigator testify  
 22 about out-of-court statements from an informant that caused him to go to a certain  
 23 location); *United States v. Munoz*, 233 F.3d 1117, 1134 (9th Cir. 2000) (no error in  
 24 allowing attorney to testify about out-of-court conversations with Michigan State  
 25 investigators that caused him to send letter requesting that investment company sales  
 26 personnel suspend investment sales); *United States v. Brown*, 923 F.2d 109, 111 (8th Cir.  
 27 1991) (out-of-court statement is not hearsay if offered for the limited purpose of  
 28 explaining why a police investigation was undertaken); *United States v. Lowe*, 767 F.2d

TRIAL BRIEF

*United States v. Marschall* - 11

UNITED STATES ATTORNEY  
 700 STEWART STREET, SUITE 5220  
 SEATTLE, WASHINGTON 98101  
 (206) 553-7970

1 1052, 1063-64 (4th Cir. 1985) (finding agent's testimony regarding information he  
 2 received from third party was not hearsay since it was offered to explain the preparations  
 3 agents took in anticipation of the accused's arrest). Similarly, law enforcement agents  
 4 who investigated the case may testify about statements made to them by these initial  
 5 tipsters during the course of the investigation. These statements will not be introduced  
 6 for their truth, but rather to explain why the investigating agents took subsequent action.

7 **E. Cross-Examination of the Defendant**

8 A defendant who testifies at his trial may be cross-examined as to all matters  
 9 reasonably related to the issues he puts in dispute during cross-examination. A defendant  
 10 has no right to avoid cross-examination on matters which call into question his claim of  
 11 innocence. *United State v. Miranda Uriarte*, 649 F.2d 1345, 1353-54 (9th Cir. 1981).

12 **F. Evidence of the Defendant's Character**

13 In general, Federal Rule of Evidence 404(a) prohibits the introduction of character  
 14 evidence to prove that a person acted in accordance with that character. Rule  
 15 404(a)(2)(A), however, creates an exception for criminal defendants: "in a criminal case .  
 16 . . a defendant may offer evidence of the defendant's pertinent trait." Thus, if the  
 17 Defendant can show that evidence of a certain trait is relevant, he might be able to  
 18 present evidence that he has that trait. Fed. R. Evid. 404(2)(A); *see United States v.*  
 19 *Franco*, CR-16-00268-001-TUC-CKJ (EJM), 2017 WL 11466629, at \*1 (D. Ariz. Sept.  
 20 7, 2017) quoting *United States v. Angelini*, 678 F.2d 380, 381 (1st Cir. 1982) (pertinent  
 21 means relevant).

22 If the Defendant could show that such character evidence was relevant, Federal  
 23 Rule of Evidence 405 further limits the form in which such evidence can be presented.  
 24 "When evidence of a person's character or character trait is admissible, it may be proved  
 25 by testimony about the person's reputation or by testimony in the form of an opinion."  
 26 Fed. R. Evid. 405. Such reputation or opinion evidence contrasts with evidence of  
 27 specific instances of conduct. *Compare* Fed. R. Evid. 405(a) *with* Fed. R. Evid. 405(b).  
 28 A defendant can introduce such specific-instance evidence about himself only when "a

1 person's character or character trait is an essential element of a charge, claim, or  
 2 defense." Fed. R. Evid. 405(b). To meet this requirement, the Defendant must show that  
 3 "proof, or failure of proof, of the character trait by itself actually satisf[ies] an element of  
 4 the charge, claim, or defense." *United States v. Keiser*, 57 F.3d 847, 856 (9th Cir. 1995).  
 5 Here, the Defendant cannot prove that character is an essential element of the charged  
 6 crime and cannot overcome this bar. Thus, he is limited to presenting character evidence  
 7 only in the form of reputation or opinion evidence.

8 Reputation evidence consists of a witness's testimony about the defendant's  
 9 reputation in the community for having the pertinent trait. As the Supreme Court  
 10 explained, the witness presenting character evidence via testimony about reputation is  
 11 "allowed to summarize what he has heard in the community" but "may not testify about  
 12 defendant's specific acts or courses of conduct or his possession of a particular  
 13 disposition or of benign mental and moral traits." *Michelson v. United States*, 335 U.S.  
 14 469, 477 (1948). Before speaking about such a reputation, the witness must establish that  
 15 he or she is familiar with the person's reputation and can "speak with authority of the  
 16 terms in which [the subject] generally is regarded." *United States v. Bedonie*, 913 F.2d  
 17 782, 802 (10th Cir. 1990). A witness providing an opinion about a defendant's character  
 18 also must have a basis for that opinion. *See United States v. Cortez*, 935 F.2d 135, 139  
 19 (8th Cir. 1991) citing *United States v. Dotson*, 799 F.2d 189, 192–93 (5th Cir.1986).

20 The Defendant, therefore, can introduce character evidence only if it is relevant  
 21 and if he does so through testimony about a well-founded opinion or about the  
 22 Defendant's reputation. While the government cannot be the first to introduce character  
 23 evidence, the government is not subject to the same limitations as to form once the  
 24 Defendant makes character an issue. In particular, the government can cross-examine  
 25 character witnesses with evidence of specific incidents. "On cross-examination of the  
 26 character witness, the court may allow an inquiry into relevant specific instances of the  
 27 person's conduct." Fed. R. Evid. 405. In addition, the government can offer its own  
 28 evidence, such as rebuttal witnesses, to refute reputation and opinion testimony about the

1 Defendant's character. Fed R. Evid. 404(a)(2)(A) ("if the evidence is admitted, the  
 2 prosecutor may offer evidence to rebut it").

3 **G. Business Records**

4 The government has presented defense counsel with a stipulation regarding the  
 5 authenticity of various records obtained from Facebook. If no stipulation is reached, the  
 6 government will introduce business records obtained from Facebook at trial through two  
 7 means. First, records from Facebook will be offered pursuant to a certification made by a  
 8 competent custodian under Fed. R. Evid. 902(11). Copies of the records themselves, as  
 9 well as the Rule 902(11) certification, have been provided to defense counsel, who have  
 10 to date raised no objection to the admission of these materials. Second, Facebook  
 11 postings will also be offered through live witnesses, including Special Agent Angela  
 12 Zigler, Karen Hogan, and Steve Koehler. Such testimony is sufficient to meet the  
 13 authenticity requirements because these individuals viewed these posts firsthand and  
 14 independently saved them.

15 **H. Certified Public Records**

16 The government intends to introduce public records, including court filings, and  
 17 has sought the defense's stipulation to the admissibility of those exhibits. To the extent  
 18 the parties cannot reach an agreement, these records will be introduced as authentic  
 19 pursuant to Federal Rule of Evidence 902(4). In addition, the records either are not  
 20 hearsay or are exceptions to the prohibition on hearsay. Under Rule 902(4), certified  
 21 copies of public records are self-authenticating. Such documents include copies "of an  
 22 official record—or a copy of a document that was recorded or filed in a public office as  
 23 authorized by law—if the copy is certified as correct by . . . the custodian or another  
 24 person authorized to make the certification." Fed. R. Evid. 902(4)(A). Pursuant to this  
 25 rule, the government intends to authenticate certified copies of court records and  
 26 government agency records.

27 These records also are admissible under the hearsay rules. Some are not hearsay  
 28 pursuant to Federal Rule of Evidence 801(d)(2). This Rule provides that an out-of-court

1 statement is not hearsay if “the statement is offered against an opposing party and . . . was  
 2 made by the party in an individual . . . capacity.” *Id.* The government intends to admit  
 3 plea agreements and agency decisions that were signed by the Defendant, and as such,  
 4 they are the Defendant’s statements and admissible.

5 Other certified public records are admissible under the public records exception to  
 6 the prohibition on hearsay. Rule 803(8) provides that “a record or statement of a public  
 7 office [that] sets out . . . the office’s activities” is “not excluded by the rule against  
 8 hearsay, regardless of whether the declarant is available.” The government intends to  
 9 admit two records under this exception: certified copies of Judgments entered by the U.S.  
 10 District Court for the Western District of Washington. These documents are records of a  
 11 public office—this Court—and set out the Court’s activities. There is no reason to doubt  
 12 the trustworthiness of these documents, and they are admissible at trial.

13 **I. Exclusion of Witnesses**

14 Pursuant to Rule 615 of the Federal Rules of Evidence, the government requests  
 15 that witnesses be excluded from the courtroom, with the exception of Special Agent  
 16 Angela Zigler, who is the case agent. *United States v. Thomas*, 835 F.2d 219, 222-23  
 17 (9th Cir. 1987); *see also United States v. Machor*, 879 F.2d 945, 953-54 (1st Cir. 1989).

18 **J. Statements of Agents and Unindicted Co-Conspirators**

19 Pursuant to Federal Rule of Evidence 801(d)(2)(D) and 801(d)(2)(E), statements  
 20 made by agents and co-conspirators of the Defendant are not hearsay. In this case, the  
 21 government will demonstrate that Rose Marschall, the Defendant’s wife, served as his  
 22 agent and unindicted co-conspirator. For example, on March 4, 2020, Rose Marschall  
 23 posted an image of a document titled “BE PREPARED,” on Facebook. This document  
 24 was authored by her husband and listed his name—“by Rick Marschall, Health Coach.”  
 25 Similarly, in March 2020, Rose Marschall posted that she “ha[d] been selling g one of the  
 26 most preventive nom’toxic treatment st a vastly reduced cost to protect myself and those  
 27 smart enough to understand the words ‘zBe Prepated.’” Additionally, on March 21,  
 28

1 2020, Rose Marschall posted “The Dynamic Duo knocked out my very bad cough/cold in  
 2 February. Corona? Want Info?” and then listed the Defendant’s phone number.

3 As the Defendant’s agent, Rose Marschall’s statements may be admitted if they  
 4 were made “on a matter within the scope of that [agent] relationship and while it existed.”  
 5 Fed. R. Evid. 801(d)(2)(D). Accordingly, her statements peddling the Dynamic Duo  
 6 products, suggesting treatments for COVID-19, or otherwise addressing the COVID-19  
 7 pandemic are admissible non-hearsay. It does not matter whether the Defendant  
 8 expressly authorized Rose Marschall to make the particular statements posted on  
 9 Facebook, so long as they were made as part of her agency relationship. *United States v.*  
 10 *Bonds*, 608 F.3d 495, 502 (9th Cir. 2010). In evaluating whether an agency relationship  
 11 exists, the Court is authorized to examine the contents of the agent’s statements. *Id.* at  
 12 504.

13 Additionally, as an unindicted co-conspirator, Rose Marschall’s statements may be  
 14 admitted as non-hearsay. Fed. R. Evid. 801(d)(2)(E) provides that statements “made by  
 15 the party’s coconspirator during and in furtherance of the conspiracy” are admissible as  
 16 non-hearsay. *See also United States v. Weiner*, 578 F.2d 757, 768 (9th Cir. 1978).  
 17 Conspiracy need not be charged in the indictment for co-conspirator statements to be  
 18 admissible. *See, e.g., id.; United States v. Lutz*, 621 F.2d 940, 947 (9th Cir. 1980)  
 19 (coconspirator statements by participants in a fraud scheme made during the perpetration  
 20 of the fraud were admissible even though they were not charged with conspiracy because  
 21 there was independent evidence that they were members of a common plan). So long as  
 22 there is evidence establishing that the two conspired to commit the charged offense, such  
 23 statements are admissible.

24 **K. Demonstrative Exhibits**

25 The government might use demonstrative exhibits at trial. If it chooses to do so,  
 26 such exhibits can be shown to the jury pursuant to Federal Rule of Evidence 611. Rule  
 27 611, addressing the Mode and Order of the Interrogation of Witnesses, gives the Court  
 28 great discretion in what a witness may use during testimony so as to “(1) make the

TRIAL BRIEF

*United States v. Marschall* - 16

UNITED STATES ATTORNEY  
 700 STEWART STREET, SUITE 5220  
 SEATTLE, WASHINGTON 98101  
 (206) 553-7970

1 presentation effective for the ascertainment of the truth, [and] (2) avoid needless  
 2 consumption of time.” Fed. R. Evid. 611(a); *see United States v. Gardner*, 611 F.2d  
 3 770,776 (9th Cir. 1980) (summary chart admissible in tax evasion case under Rule  
 4 611(a)); *United States v. Paulino*, 935 F.2d 739, 752-54 (6th Cir. 1991) (testimony of  
 5 non-expert summary witness regarding cash generated from cocaine sales in drug  
 6 conspiracy case admissible under Rule 611(a) where trial court gave limiting instruction  
 7 and defense had full opportunity to cross-examine); *United States v. Scales*, 594 F.2d  
 8 558, 563-64 (6th Cir. 1979) (summaries of testimonial evidence designed “to aid the jury  
 9 in its examination of the evidence already admitted” do not come within Rule 1006, but  
 10 are authorized by Rule 611(a)); *see also* 5 Jack B. Weinstein and Margaret A. Berger,  
 11 Weinstein’s Evidence, at ¶ 1006[03] (summary “prepared by a witness from his own  
 12 knowledge to assist the jury in understanding or remembering a mass of details is  
 13 admissible, not under Rule 1006, but under such general principles of good sense as are  
 14 embodied in Rule 611(a)”). The substantive content must be authenticated, but that may  
 15 be done by the summary witness, if the witness has reviewed the underlying evidence.  
 16 Fed. R. Evid. 901; *United States v. Soulard*, 730 F.2d 1291, 1299 (9th Cir. 1984).  
 17 Moreover, Rule 1006 allows for the summaries of voluminous materials to be admissible  
 18 and used as substantive evidence, rather than solely as demonstrative evidence. *See*  
 19 *United States v. Meyers*, 847 F.2d 1408, 1411 12 (9th Cir. 1988) (admitting summary of  
 20 otherwise admissible evidence as substantive evidence where the summary contributed to  
 21 the clarity of the presentation). These exhibits will be produced to defense counsel in  
 22 advance of trial and all underlying documents have been produced in discovery.

### 23 **L. Stipulations**

24 The government has proposed two stipulations to the defense. One relates to the  
 25 admissibility of the plea agreements in the Defendant’s two previous federal criminal  
 26 cases. The other relates to the authentication of certified and business records. The  
 27 defense is considering these stipulations, and if the parties enter into any stipulations, we  
 28 will file them before trial and seek to introduce them at the appropriate time.

#### IV. POSSIBLE DEFENSES

The Defendant has provided notice that he intends to pursue an entrapment by estoppel defense. The government may provide further briefing regarding the inadmissibility of this defense in advance of, or during, trial. At this point, the government is attempting to reach an agreement with the defense regarding this evidence and will file a motion *in limine* if no such agreement is reached.

In short, the government does not believe that the Defendant can satisfy the elements establishing entrapment by estoppel. In order to invoke an entrapment by estoppel defense, the Defendant must show that:

(1) an authorized government official, empowered to render the claimed erroneous advice, (2) who has been made aware of all the relevant historical facts, (3) affirmatively told [the defendant] the proscribed conduct was permissible, (4) that [the defendant] relied on the false information, and (5) that [the] reliance was reasonable.

*United States v. Batterjee*, 361 F.3d 1210, 1216 (9th Cir. 2004). The Defendant's "reliance is [only] reasonable if a person sincerely desirous of obeying the law would have accepted the information as true, and would not have been put on notice to make further inquiries." *Id.* at 1216-17.

The Defendant’s proposed defense fails because he cannot show at least two of these elements, (1) that a federal official was aware of all the relevant facts and (2) affirmatively told the Defendant that his actions were legal. The Defendant neither advised the federal government that he was selling a purported COVID-19 cure nor was the Defendant told that selling the Dynamic Duo products was legal. As the cases cited in the Defendant’s prior motion *in limine* demonstrate, it is not sufficient for a defendant to simply rely on a federal official’s vague or general advice made without knowledge of a defendant’s specific illegal conduct. Dkt. 98. Rather, for an entrapment by estoppel defense to apply, a federal official must affirmatively tell a defendant that a specific course of action is permissible.

1 For example, in *Raley v. Ohio*, 360 U.S. 423, 425-26 (1959), the Court permitted  
 2 an entrapment by estoppel defense, vacating the defendants' convictions for refusal to  
 3 answer questions posed by the Ohio Un-American Activities Committee. In permitting  
 4 this defense, the Court noted that, immediately prior to their refusal, the Commission  
 5 expressly informed the defendants of their privilege against self-incrimination. *Id.*  
 6 Similarly, in *Cox v. Louisiana*, 379 U.S. 559, 572 (1965), the Court permitted an  
 7 entrapment by estoppel defense, vacating a conviction for picketing near a Louisiana  
 8 court, noting that, immediately prior, a police officer had informed the defendant that  
 9 picketing at that location was legal. Additionally, in *United States v. Pennsylvania Indus.  
 10 Chem. Corp.*, 411 U.S. 665, 673 (1973), the Court vacated a conviction for discharging  
 11 pollutants after the Corps of Engineers told the defendants that the specific discharge  
 12 would not violate the law. In *United States v. Tallmadge*, 829 F.2d 767, 774 (9th Cir.  
 13 1987), the Ninth Circuit also permitted an entrapment by estoppel defense, vacating a  
 14 conviction for felon in possession of a firearm after a federal firearms dealer expressly  
 15 told the defendant that his prior felony did not bar his ability to purchase a gun. Finally,  
 16 in *Batterjee*, 361 F.3d at 1216-17, the Ninth Circuit vacated a firearms conviction after a  
 17 federal firearms dealer told the defendant that his immigration status did not bar his gun  
 18 purchase.

19 The Defendant cannot establish entrapment by estoppel because he did not advise  
 20 a federal government official of all of the relevant facts related to the *charged crime*  
 21 before he committed it and no federal official affirmatively told him, after reviewing  
 22 those facts, that the *conduct charged* was lawful. Unlike the defendants in the above-  
 23 cited cases, the Defendant never approached the government, disclosing his proposal to  
 24 sell the Dynamic Duo products or explaining his intent to sell an unapproved drug. And  
 25 unlike the defendants in the above-cited cases, no federal official advised the Defendant,  
 26 after reviewing his sales proposal, that selling the Dynamic Duo products was legal.  
 27 Instead, the government was wholly unaware of the Defendant's offenses until he had  
 28

1 already begun selling his purported COVID-19 cure in 2020. Nothing in the Defendant's  
2 two prior plea agreements, entered into in 2011 and 2017, alters these conclusions.

3 The Defendant has not provided notice of any other defense for which the Federal  
4 Rules of Criminal Procedure require notice. Therefore, the government would move to  
5 bar any such defense if it were raised during trial.

6 **V. RECIPROCAL DISCOVERY**

7 To date, the government has provided over 800 pages of discovery to the defense.  
8 Since the inception of this prosecution, the United States has made available for the  
9 defense review all of the items of evidence, whether intended to be used as trial exhibits  
10 or not, over which the government has control or custody. The United States has not  
11 received any reciprocal discovery from the defense and will seek to exclude any offered  
12 during the course of trial that should have been provided previously, pursuant to Rule  
13 16(d)(2) of the Federal Rules of Criminal Procedure.

14 **VI. MOTIONS IN LIMINE**

15 Aside from the aforementioned entrapment by estoppel issue, the United States  
16 has fully briefed all expected legal issues in advance of trial and does not have any  
17 further motions *in limine*.

18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

## VII. CONCLUSION

The government is not aware of other legal issues that are likely to arise during the course of this trial. If other issues do arise, the government will address those issues by way of a supplemental brief or briefs.

DATED July 19, 2021.

TESSA M. GORMAN  
Acting United States Attorney

/s/ Marie M. Dalton  
MARIE M. DALTON  
NICHOLAS MANHEIM  
Assistant United States Attorneys  
United States Attorney's Office

## **CERTIFICATE OF SERVICE**

I hereby certify that on July 19, 2021, I have electronically filed the foregoing with the Clerk of the Court using the CM/ECF system that will send notification of such filing to the attorney of record for the defendant.

s/ Marwa Hirmendi  
MARWA HIRMENDI  
Legal Assistant  
United States Attorney's Office  
700 Stewart Street, Suite 5220  
Seattle, Washington 98101-1271  
Phone: (206) 553-4750  
FAX: (206) 553-0882  
E-mail: marwa.hirmendi@usdoj.gov